DNA X, Inc.
SONM
$4.75
$0.010.21%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 146.70% | -237.97% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 110.77% | -266.29% | |||
| Operating Income | -158.58% | 255.18% | |||
| Income Before Tax | -178.48% | 207.33% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -175.05% | 210.12% | |||
| Earnings from Discontinued Operations | 172.71% | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 171.34% | -86.98% | |||
| EBIT | -158.58% | 255.18% | |||
| EBITDA | -133.15% | 353.37% | |||
| EPS Basic | 153.49% | -94.16% | |||
| Normalized Basic EPS | -130.37% | 315.95% | |||
| EPS Diluted | 153.89% | -92.55% | |||
| Normalized Diluted EPS | -130.37% | 315.95% | |||
| Average Basic Shares Outstanding | 75.05% | -26.62% | |||
| Average Diluted Shares Outstanding | 75.05% | -26.62% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||